Takeda Books $2.5 Billion Provision Related to Amitiza Antitrust Litigation
By Kosaku Narioka
Takeda Pharmaceutical revised its annual results to a net loss after booking a provision of $2.52 billion for antitrust litigation related to constipation drug Amitiza.
The Japanese drugmaker said Friday that it booked an additional provision for legal proceedings of 402.5 billion yen and recorded a net loss of Y152.39 billion for the fiscal year ended March.
The company previously reported net profit of Y191.76 billion.
Takeda said in May that a jury in the U.S. District Court for the District of Massachusetts returned a verdict against the company in the Amitiza antitrust litigation and that it was assessing the amount of the provision to be recognized for the year ended March.
The drugmaker said Friday that it didn't expect the antitrust litigation to materially affect its earnings forecasts for this fiscal year.
Takeda also said the amount of any liability to be imposed on the company hasn't been finalized. The company intends to pursue posttrial motions and an appeal and will seek a stay of execution of the judgment during the pendency of the appeal, it said.
Write to Kosaku Narioka at kosaku.narioka@wsj.com
(END) Dow Jones Newswires
June 05, 2026 03:52 ET (07:52 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Dividend Stocks
12 Best Blue-Chip Stocks to Buy for the Long Term
United States